Originally from South Eastern France, Chris obtained his Ph.D. in 2010 under the guidance of Professor Jean Rodriguez and Prof. Thierry Constantieux at the Aix-Marseille Université. After three years of postdoctoral studies working with Prof. Bill Roush at Scripps Florida, Chris joined Pfizer in Groton, CT (USA) as a medicinal chemist where he advanced several projects to clinical candidate nomination. In 2017, he switched gear and joined the Chemical Research and Development (CRD) department where he contributed to the design of chemical processes for Pfizer APIs and led multiple early programs through the clinic. In 2020, he was responsible for the initial clinical deliveries of nirmatrelvir, active ingredient of Pfizer COVID-19 oral inhibitor PAXLOVID, and helped advance the drug candidate at lightspeed. He is now an Associate Research Fellow and recently took on the Sustainable Chemistry Lead role for Pfizer CRD to drive the entire Portfolio towards greener goals. Chris has co-authored more than 45 peer-reviewed publications, reviews, book chapters and patents. He received the Young Investigator Award from the American Chemical Society in 2021, as well as the ACS Heroes of Chemistry in 2022 for his contributions to PAXLOVID.